Aranda Pharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$790K
- Investors
-
3
Aranda Pharma General Information
Description
Developer of novel antiandrogen drugs intended to combat prostate cancer and neurodegenerative diseases. The company's drugs are made of small molecules and androgen receptor antagonists that are non-toxic, and provide effective treatments for hair loss and acne, which are underrepresented drug targets despite being validated without affecting hormonal function in other parts of the body, enabling clients to improve the quality of life for millions of people suffering from hair loss and acne.
Contact Information
Website
www.arandapharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Microkatu 1
- PO Box 1199
- 70211 Kuopio
- Finland
+358 044 0000000
Aranda Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Equity Crowdfunding | 30-Dec-2021 | $790K | 00.000 | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC | 21-May-2018 | 00.000 | 00.000 | 00.000 | Completed | Startup |
| 1. Seed Round | 04-Nov-2015 | Completed | Startup |
Aranda Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | 000,000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Aranda Pharma Patents
Aranda Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3004118-A1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | 0000000000 | |
| EP-3004118-B1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | 0000000000 | |
| ES-2715877-T3 | Use of fused benzo [b] thiazine derivatives as cytoprotectors | Active | 31-May-2013 | 0000000000 | |
| US-9827249-B2 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | 0000000000 | 0 |
| US-20160106754-A1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | A61K31/542 |
Aranda Pharma Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mika Käyhkö | Chief Executive Officer | ||
| Anu Muona Ph.D | Co-Founder & Chief Operating Officer | ||
| Heikki Eronen | Manager of Company Administration and Finance | ||
| Milla Koistinaho Ph.D | Co-Founder & Board Member |
Aranda Pharma Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Erkki Tenhunen | Self | Board Member | 000 0000 |
| Mikko Mannerkoski | Self | Chairman | 000 0000 |
| Milla Koistinaho Ph.D | Self | Co-Founder & Board Member | 000 0000 |
Aranda Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aranda Pharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Innovestor | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Finnvera | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
| Tarrex Biopharma | Corporation | Minority | 000 0000 | 000000 0 |